Long-Term Follow-Up of an Intensified Myeloablative Conditioning Regimen with In Vivo T Cell Depletion Followed by Allografting in Patients with Advanced Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 6, 2010, Pages 861-864

  Kröger, Nicolaus ^a   Einsele, Hermann ^b   Derigs, Günter ^c   Wandt, Hannes ^d   Krüll, Andreas ^a   Zander, Axel ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d KLINIKUM NÜRNBERG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Antithymocyte globulin; Multiple myeloma; Myeloablative conditioning regimen; Total marrow irradiation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; T CELL DEPLETION; WHOLE BODY RADIATION;

ADULT; ANTILYMPHOCYTE SERUM; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVORS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 77952571251     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.01.018     Document Type: Article

References (14)

1. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
2. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
3. Hunter H.M., Peggs K., Powles R., et al. Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT). Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning: evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005, 128:496-502.
4. Crawley C., Iacobelli S., Bjorkstrand B., et al. Reduced-intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning. Blood 2007, 109:3588-3594.
5. Gahrton G., Svenson H., Cavo M., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-3 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 13:209-216.
6. Rabitsch W., Prinz E., Ackermann J., et al. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation. Eur J Haematol 2004, 72:26-31.
7. Majolino I., Corradini P., Scime R., et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998, 22:449-455.
8. Kröger N., Einsele H., Wolff D., et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma: a phase I/II study of the German Study Group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003, 31:973-979.
9. Ayuk F.A., Fang L., Fehse B., et al. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005, 33:1531-1536.
10. Ayuk F., Perez-Simon J.A., Shimoni A., et al. Clinical impact of human Jurkat T-cell line derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008, 93:1343-1350.
11. Björkstrand B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplanation vs autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
12. Kröger N., Krüger W., Renges W., et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001, 112:421-423.
13. Kröger N., Shimoni A., Zagrivnaja M., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104:3361-3363.
14. Kröger N. Mini-midi-maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 2007, 21:1851-1858.